Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis.

[1]  M. Denton,et al.  Can Burkholderia cepacia complex be eradicated with nebulised amiloride and TOBI? , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[2]  L. Kalish,et al.  Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. , 2006, American journal of respiratory and critical care medicine.

[3]  B. Williams,et al.  Combination aerosol therapy to treat Burkholderia cepacia complex , 2005, European Respiratory Journal.

[4]  M. Dodd,et al.  Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis , 2004, Thorax.

[5]  J. Lipuma.  Burkholderia cepacia Complex as Human Pathogens. , 2003, Journal of nematology.

[6]  J. Goehrs,et al.  Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients , 2003, Quality of Life Research.

[7]  P. Chaumet‐Riffaud,et al.  French multicenter randomized double‐blind placebo‐controlled trial on nebulized amiloride in cystic fibrosis patients , 2000, Pediatric pulmonology.

[8]  J. Raboud,et al.  Burkholderia cepacia in cystic fibrosis. Variable disease course. , 1999, American journal of respiratory and critical care medicine.

[9]  M S Pepe,et al.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. , 1999, The New England journal of medicine.

[10]  M. Knowles,et al.  Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways. , 1997, Chest.

[11]  R. Cohn,et al.  Substituted amines synergistic with tobramycin against Burkholderia cepacia in vitro. , 1997, Chemotherapy.

[12]  E. Bignamini,et al.  Concentration of inhaled amiloride in cystic fibrosis , 1996, The Lancet.

[13]  M. Whiteford,et al.  Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. , 1995, Thorax.

[14]  R. Cohn,et al.  In vitro suppression of Pseudomonas cepacia after limited exposure to subinhibitory concentrations of amiloride and 5‐(N,N‐hexamethylene) amiloride , 1994, Pediatric pulmonology.

[15]  D. Geddes,et al.  No added benefit from nebulized amiloride in patients with cystic fibrosis. , 1993, The European respiratory journal.

[16]  M. King,et al.  A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. , 1990, The New England journal of medicine.

[17]  M. King,et al.  Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. , 1990, The American review of respiratory disease.

[18]  M. Jacobs,et al.  In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis , 1988, Antimicrobial Agents and Chemotherapy.

[19]  R. Stern,et al.  Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. , 1987, Chest.

[20]  L. Cantley,et al.  Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. , 1986, The Journal of clinical investigation.

[21]  P. Gilligan,et al.  Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. , 1985, The Journal of pediatrics.

[22]  M. Knowles,et al.  Bioelectric properties and ion flow across excised human bronchi. , 1984, Journal of applied physiology: respiratory, environmental and exercise physiology.

[23]  M. Corey,et al.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. , 1984, The Journal of pediatrics.

[24]  M. Knowles,et al.  Abnormal ion permeation through cystic fibrosis respiratory epithelium. , 1983, Science.

[25]  M. Knowles,et al.  Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. , 1981, The New England journal of medicine.

[26]  S. Rizvi,et al.  Risk factors and outcome , 2008 .

[27]  J. Lipuma,et al.  Burkholderia cepacia in cystic fibrosis. , 1995, The New England journal of medicine.

[28]  S. Aronoff,et al.  The effect of sodium on amiloride-tobramycin synergy in Pseudomonas cepacia. , 1989, The Journal of laboratory and clinical medicine.

[29]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.